Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has entered into a series of agreements with Aurobindo Pharma, an Indian pharmaceutical company, to commercialize medicines that are no longer patent protected, and have lost market exclusivity in the US and Europe, further progressing its established products business unit strategy.
Subscribe to our email newsletter
Under the terms of the agreements, Pfizer has acquired rights to 39 generic solid oral dose products in the US and 20 in Europe, plus an additional 11 in France. These medicines cover a broad range of therapeutic areas including cardiovascular disease and central nervous system disorders, and will be commercialized in the US through Pfizer’s Greenstone subsidiary.
Pfizer has also acquired rights to 12 sterile injectable products in the US and Europe. These medicines are antibiotics including penicillins and cephalosporins.
These agreements are an expansion of a five-product US deal Pfizer and Aurobindo entered into in July 2008. Together, the two transactions bring 44 solid oral dose products to Pfizer’s diversified existing portfolio of established brands in the US. Financial terms were not disclosed.
David Simmons, president and general manager of established products business unit at Pfizer, said: “We will dramatically change Pfizer’s established products portfolio to an engine of positive growth. These agreements represent solid, measurable progress, and a strong commitment to achieve our growth objectives.”